Sigyn Therapeutics

Sigyn Therapeutics, Inc. is a development-stage company, which focuses on creating therapeutic solutions that address unmet needs in global health. The company is headquartered in Beverly Hills, California and currently employs 4 full-time employees. The company went IPO on 2016-01-28. The firm's lead therapeutic candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Candidate treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines. Its development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. Its ImmunePrep platform enhances the performance of immunotherapeutic antibodies.